In the last 20 years, numerous clinical studies have been conducted concerning the prophylactic administration of GnRH agonists alongside chemotherapy in women with breast cancer [24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]. This evidence concerns the gene GNRH1 and breast cancer.